Possibilities of improving the effectiveness of treatment of manifestations of metabolic syndrome in the elderly (on the example of taurine)
https://doi.org/10.31146/1682-8658-ecg-204-8-171-178
Abstract
The article presents modern data on the formation and manifestations of multiple metabolic disorders with an emphasis on the features of pathology in old age. Age-related changes in nutrition, physical activity, carbohydrate and lipid metabolism are additional risk factors for the development of metabolic syndrome and determine the high prevalence of this pathology in old age. Multiple metabolic disorders aggravate the course of each of them and worsen the prognosis due to high risks of cardiovascular and other types of mortality. Timely diagnosis and effective correction of metabolic syndrome manifestations will reduce these risks and increase life expectancy while improving its quality. In order to increase the effectiveness of basic therapy of metabolic disorders, the use of drugs capable of positively affecting multiple metabolic disorders has been shown. In particular, this paper provides an evidence base for the effectiveness of taurine in patients with metabolic syndrome. When using taurine in addition to basic standard therapy, there is a significant decrease in blood pressure, glucose levels, insulin, serum lipid spectrum, body mass index.
About the Author
E. V. Golovanova
Moscow State University of Medicine and Density n. a. A. I. Evdokimov
Russian Federation
Russian Federation
References
1. Clinical guidelines for the diagnosis and treatment of metabolic syndrome, Available: https://mzdrav.rk.gov.ru/file/mzdrav18042014_Klinicheskie_rekomendaciiMetabolicheskij sindrom.pdf, (2013), Access: 07/02/2021.@@ Клинические рекомендации по диагностике и лечению метаболического синдрома, https://mzdrav.rk.gov.ru/file/mzdrav18042014_Klinicheskie_rekomendaciiMetabolicheskij sindrom.pdf, (2013), обращение от 02.07.2021.
2. Mychka V.B., Vertkin A. L., Vardaev L. I., et al. Experts’ consensus on the interdisciplinary approach towards the management, diagnostics, and treatment of patients with metabolic syndrome. Cardiovascular Therapy and Prevention. 2013;12(6):41-82. (In Russ.)@@ Мычка В. Б., Верткин А. Л., Вардаев Л. И. и соавт. Консенсус экспертов по междисциплинарному подходу к ведению, диагностике и лечению больных с метаболическим синдромом. Кардиоваскулярная терапия и профилактика. 2013;12(6):41-82.
3. Eslam M., Newsome P. N., Sarin S. K., et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039
4. Eslam M., Sanyal A. J., George J.; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1. doi:10.1053/j.gastro.2019.11.312.
5. Angulo P, Kleiner DE, Dam-Larsen S et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes patients with nonalcoholic fatty liver disease. Gastroenterology. 2015 Aug;149(2):389-97.e10. doi: 10.1053/j.gastro.2015.04.043.
6. Tereshina E. V. Metabolic disorders - the basis of age-dependent diseases or aging of the body? State of the problem. Advances in gerontology, 2009;22(1):129-138. (in Russ.)@@ Терешина Е. В. Метаболические нарушения - основа зависимых от возраста заболеваний или старение организма? Состояние проблемы // Успехи геронтологии, 2009. - Т. 22. - № 1. - С. 129-138.
7. Shestakova M. V. Diabetes mellitus in the elderly: features of the clinic, diagnosis and treatment. Consilium Medicum, 2002;4(10):544-551. (in Russ.)@@ Шестакова М. В. Cахарный диабет в пожилом возрасте: особенности клиники, диагностики и лечения. Consilium Medicum, 2002;4(10):544-551.
8. Korkushko O. V. Cardiovascular system and age: clinical and physiological aspects. Moscow. Medicine, 1983. 176 p.@@ Коркушко О. В. Сердечно-сосудистая система и возраст: клинико-физиологические аспекты. - М.: Медицина, 1983. - 176 с.
9. Sadulaeva I. A. Rhythm disturbances in metabolic syndrome. Medical Bulletin, 2009; 36:505 (in Russ.)@@ Садулаева И. А. Нарушения ритма при метаболическом синдроме. - Медицинский вестник, 2009. - № 36 (505)
10. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004.
11. Lazebnik L. B., Golovanova E. V., Turkina S. V., et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4-52. (In Russ.) doi: 10.31146/1682-8658-ecg-185-1-4-52.@@ Лазебник Л. Б., Голованова Е. В., Туркина С. В., и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;1(1):4-52. doi: 10.31146/1682-8658-ecg-185-1-4-52.
12. Ivashkin V. T., Mayevskaya M. V., Pavlov C. S., et al. Diagnostics and treatment of non-alcoholic fatty liver disease: clinical guidelines of the Russian Scientific Liver Society and the Russian gastroenterological association.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(2):24-42. (In Russ.) doi: 10.22416/1382-4376-2016-26-2-24-42.@@ Ивашкин В. Т., Маевская М. В., Павлов Ч. С., и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(2):24-42. doi: 10.22416/1382-4376-2016-26-2-24-42.
13. Romero-Gómez M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017 Oct;67(4):829-846. doi: 10.1016/j.jhep.2017.05.016.
14. Cho. The Impact of Weight Changes on Nonalcoholic Fatty Liver Disease in Adult Men with Normal Weig. Korean J Fam Med. 2014 Sep;35(5):243-50. doi: 10.4082/kjfm.2014.35.5.243.
15. Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001 Nov;74(5):579-84. doi: 10.1093/ajcn/74.5.579.
16. Murakami S. The physiological and pathophysiological roles of taurine in adipose tissue in relation to obesity. Life Sci. 2017 Oct 1;186:80-86. doi: 10.1016/j.lfs.2017.08.008.
17. Murakami S. Role of taurine in the pathogenesis of obesity. Mol Nutr Food Res. 2015 Jul;59(7):1353-63. doi: 10.1002/mnfr.201500067.
18. Imae M., Asano T., Murakami S. Potential role of taurine in the prevention of diabetes and metabolic syndrome. Amino Acids. 2014 Jan;46(1):81-8. doi: 10.1007/s00726-012-1434-4.
19. Yamori, Y., Liu, L., Ikeda, K., Miura, A., et al., Distribution of twenty-four hour urinary taurine excretion and association with ischemic heart disease mortality in 24 populations of 16 countries: results from the WHO-CARDIAC study. Hypertens Res. 2001 Jul;24(4):453-7. doi: 10.1291/hypres.24.453.
20. Yamori, Y., Taguchi, T., Mori, H., Mori, M., Low cardiovascular risks in the middle aged males and females excreting greater 24-hour urinary taurine and magnesium in 41 WHO-CARDIAC study populations in the world. J Biomed Sci. 2010 Aug 24;17 Suppl 1(Suppl 1): S21. doi: 10.1186/1423-0127-17-S1-S21.
21. Jeevanandam M., Young D. H., Ramias L., Schiller W. R. Effect of major trauma on plasma free amino acid concentrations in geriatric patients. Am J Clin Nutr. 1990 Jun;51(6):1040-5. doi: 10.1093/ajcn/51.6.1040.
22. Ibrahim E.l. Agouza, et al.Comparison between serum taurine and specific tumor markers For early detection and diagnosis of HCC in egyptian patients. World Journal of Advance Healthcare Research. Volume 3, Issue 1. 2019, p. 99-106.
23. Rosa, F. T., Freitas, E. C., Deminice, R., Jord˜ao, A. A., et al., Oxidative stress and in ammation in obesity after taurine supplementation: a double-blind, placebo-controlled study. Eur J Nutr. 2014 Apr;53(3):823-30. doi: 10.1007/s00394-013-0586-7.
24. Agouza E.l., et al. Serum Taurine Level in Relation to Ophthalmoscopic Examination as Early Marker for Diabetic Retinopathy. Clin Med Biochemistry. 2017;3(1):124. doi: 10.4172/2471-2663.1000124.
25. Agouza E.I., et al. The Possibility of using Serum Taurine Level as an Early Marker to Control Complications of Diabetic Foot. J Diabetic Complications Med. 2017;2: 116. doi: 10.4172/2475-3211.1000116.
26. Sagara M., Murakami S., Mizushima S., et al. Taurine in 24-h urine samples is inversely related to cardiovascular risks of middle aged subjects in 50 populations of the world. Adv Exp Med Biol. 2015;803:623-36. doi: 10.1007/978-3-319-15126-7_50.
27. Yamori Y., Liu L., Ikeda K., Miura A., et al., Distribution of twenty-four hour urinary taurine excretion and association with ischemic heart disease mortality in 24 populations of 16 countries: results from the WHO-CARDIAC study. Hypertens Res. 2001 Jul;24(4):453-7. doi: 10.1291/hypres.24.453.
28. Yamori Y., Taguchi T., Mori H., Mori M. Low cardiovascular risks in the middle aged males and females excreting greater 24-hour urinary taurine and magnesium in 41 WHO-CARDIAC study populations in the world. J. Biomed. Sci. 2010, 1(17 Suppl), S21. J Biomed Sci. 2010 Aug 24;17 Suppl 1(Suppl 1): S21. doi: 10.1186/1423-0127-17-S1-S21.
29. Luciano A Silva, Paulo C L Silveira, et al. Taurine supplementation decreases oxidative stress in skeletal muscle after eccentric exercise. Cell Biochem Funct. Jan-Feb 2011;29(1):43-9. doi: 10.1002/cbf.1716.
30. Vahid Maleki, et al. The effects of taurine supplementation on glycemic control and serum lipid profile in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Amino Acids 2020;52: 905-914. doi: 10.1007/s00726-020-02859-8.
31. Fatemeh Esmaeili, et al. The effects of taurine supplementation on metabolic profiles, pentosidine, soluble receptor of advanced glycation end products and methylglyoxal in patients with type 2 diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Can J Diabetes. 2021 Feb;45(1):39-46. doi: 10.1016/j.jcjd.2020.05.004.
32. Waldron M., Patterson S. D., Tallent J., Jeffries O. The Effects of Oral Taurine on Resting Blood Pressure in Humans: a Meta-Analysis. Curr Hypertens Rep. 2018 Jul 13;20(9):81. doi: 10.1007/s11906-018-0881-z.
33. Guan L., Miao P. The effects of taurine supplementation on obesity, blood pressure and lipid profile: A meta-analysis of randomized controlled trials. Eur J Pharmacol. 2020 Oct 15;885:173533. doi: 10.1016/j.ejphar.2020.173533.
34. Nechaeva G.I., Druk I. V., Ryapolova E. A. «Efficacy and tolerability of taurine in patients with type 2 diabetes mellitus and left ventricular diastolic dysfunction». Polyclinic. 2015; 1:58-62. (in Russ.)@@ Нечаева Г. И., Друк И. В., Ряполова Е. А. «Эффективность и переносимость таурина у пациентов с сахарным диабетом 2-го типа и диастолической дисфункцией левого желудочка». Поликлиника. 2015; 1: 58-62.
35. Statsenko M. E. et al. «Possibilities of taurine in the complex therapy of patients with chronic heart failure and type 2 diabetes mellitus». Medical alphabet. 2015; 4(1):5-10. (in Russ.)@@ Стаценко М. Е. и соавт. «Возможности таурина в комплексной терапии больных хронической сердечной недостаточности и сахарного диабета второго типа». Медицинский алфавит. 2015; 4 (1): 5-10).
36. Yuzhakova A.E., Nechaeva A. A., Khasanova Yu.V. «The role of taurine in the correction of carbohydrate metabolism disorders». Effective Pharmacotherapy. 2019; 15(22):16-18. (in Russ.) doi: 10.33978/2307-3586-2019-15-22-16-18.@@ Южакова А. Е., Нечаева А. А., Хасанова Ю. В. «Роль таурина в коррекции нарушений углеводного обмена». Эффективная фармакотерапия. 2019; 15(22).
37. Statsenko M.E., Turkina S. V., et al. «Pharmacotherapy for non-alcoholic fatty liver disease: a focus on fibrosis». breast cancer. RMJ (Medical review). 2018; 2(1). (in Russ.)@@ Стаценко М. Е., Туркина С. В. и соавт. «Фармакотерапия неалкогольной жировой болезни печени: акцент на фиброз». РМЖ. Медицинское обозрение. 2018; 2(1).
38. Statsenko M.E., Turkina S. V., et al. «Effect of taurine on the level of visceral adiposity and the severity of visceral fat dysfunction in patients with non-alcoholic fatty liver disease». Consilium Medicum. 2019; 21(12). (in Russ.)@@ Стаценко М. Е., Туркина С. В. и соавт. «Влияние таурина на уровень висцерального ожирения и выраженность дисфункции висцерального жира у пациентов с неалкогольной жировой болезнью печени». Consilium Medicum. 2019; 21 (12).
39. Statsenko M.E. et al. Taurine in the treatment of chronic heart failure and type 2 diabetes mellitus: effects on microcirculation and elastic properties of the great vessels. Journal of Heart Failure. 2013; fourteen; 6 (80): 347-343. (in Russ.)@@ Стаценко М. Е. и соавт. «Таурин в терапии хронической сердечной недостаточности и сахарного диабета 2 типа: влияние на микроциркуляцию и эластические свойства магистральных сосудов». Журнал Сердечная Недостаточность. 2013; 14; 6 (80): 347-343.
Review
For citations:
Golovanova E.V. Possibilities of improving the effectiveness of treatment of manifestations of metabolic syndrome in the elderly (on the example of taurine). Experimental and Clinical Gastroenterology. 2022;(8):171-178. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-204-8-171-178
Views:
296
Email this article 